Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0.9
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans....
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is 'expensive' on EV/EBITDA.
Data is available to registered users only
